Pexidartinib and Sirolimus Sarcoma Phase 1 1 A Phase 1 study of the combination of pexidartinib and sirolimus to target tumor associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors

1 Division of Hematology and Oncology, Columbia University Irving Medical Center, and New York Presbyterian Hospital, Herbert Irving Pavilion, New York, NY; 2 Herbert Irving Comprehensive Cancer Center, New York, NY; Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO; 4 Division of Pediatric Hematology/Oncology, St. Louis Children’s Hospital, St Louis, MO, 5 Siteman Cancer Center, St. Louis MO. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA.; Division of Hematology-Oncology, Lifespan Cancer Institute, Warren-Alpert Medical School of Brown University, Providence, RI, USA. Program for